Takeda expands gastroenterology efforts: Announces collaboration with NuBiyota: 3 insights

Osaka, Japan-based Takeda Pharmaceuticals entered into a strategic collaboration with Teaneck, N.J.-based NuBiyota for its microbial ecosystem therapeutic products.

Here's what you should know.

1. Takeda and NuBiyota are collaborating on oral microbial consortia products, which NuBiyota will develop.

2. Takeda will pay NuBiyota an upfront payment as well as several developmental, regulatory, commercial and sales-based incentives.

3. Takeda recently entered into a similar agreement with Finch Therapeutics over its inflammatory bowel disease treatment.

More articles on gastroenterology:
Adrienne Wilson Liver Cancer Association awards Dr. Amit Singal the Blue Faery Award: 4 insights
GI leader to know: Dr. Seth Gross of NYU Langone Medical Center
Pfizer awards Dr. Declan McCole $150k grant for IBD research: 4 insights

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers